Ken Griffin Prothena Corp Public LTD CO Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Citadel Advisors LLC holds 33,600 shares of PRTA stock, worth $522,816. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,600

Previous 20,900 60.77%

Holding current value

$522,816

Previous $349,000 33.24%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$11.95 - $18.35 $2.34 Million - $3.6 Million	-196,165 Reduced 82.53%	41,518 $575,000
Q3 2024 Nov 14, 2024	SELL	$16.73 - $24.79 $1.93 Million - $2.86 Million	-115,470 Reduced 32.7%	237,683 $3.98 Million
Q2 2024 Aug 14, 2024	BUY	$19.54 - $26.15 $2.31 Million - $3.09 Million	118,227 Added 50.33%	353,153 $7.29 Million
Q1 2024 May 15, 2024	BUY	$24.75 - $40.66 $2.38 Million - $3.92 Million	96,339 Added 69.52%	234,926 $5.82 Million
Q4 2023 Feb 14, 2024	SELL	$32.31 - $52.32 $334,343 - $541,407	-10,348 Reduced 6.95%	138,587 $5.04 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $6.08 Million - $9.07 Million	128,493 Added 628.57%	148,935 $7.19 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $832,919 - $1.36 Million	-17,259 Reduced 45.78%	20,442 $1.4 Million
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $1.76 Million - $2.18 Million	37,452 Added 15040.96%	37,701 $1.83 Million
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $9.81 Million - $12.2 Million	-188,394 Reduced 99.87%	249 $15,000
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $833,601 - $2.01 Million	33,132 Added 21.31%	188,643 $11.4 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $2.55 Million - $4.48 Million	111,996 Added 257.37%	155,511 $4.22 Million
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $478,931 - $778,758	15,822 Added 57.13%	43,515 $1.59 Million
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $3.19 Million - $5.55 Million	-75,812 Reduced 73.24%	27,693 $1.37 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $2.28 Million - $3.73 Million	47,232 Added 83.93%	103,505 $7.37 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $167,629 - $430,349	15,239 Added 37.14%	56,273 $1.41 Million
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $822,310 - $1.13 Million	-81,256 Reduced 66.45%	41,034 $493,000
Q3 2020 Nov 16, 2020	SELL	$9.93 - $13.47 $729,596 - $989,694	-73,474 Reduced 37.53%	122,290 $1.22 Million
Q2 2020 Aug 14, 2020	SELL	$9.56 - $12.51 $5.36 Million - $7.01 Million	-560,667 Reduced 74.12%	195,764 $2.05 Million
Q1 2020 May 15, 2020	SELL	$7.54 - $15.77 $1.27 Million - $2.65 Million	-167,775 Reduced 18.15%	756,431 $8.09 Million
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $3.49 Million - $7.93 Million	-466,106 Reduced 33.53%	924,206 $14.6 Million
Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $697,888 - $1.06 Million	-101,290 Reduced 6.79%	1,390,312 $10.9 Million
Q2 2019 Aug 14, 2019	BUY	$8.85 - $12.49 $343,813 - $485,224	38,849 Added 2.67%	1,491,602 $15.8 Million
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $2.64 Million - $3.7 Million	255,589 Added 21.35%	1,452,753 $0
Q4 2018 Feb 14, 2019	BUY	$8.73 - $13.74 $5.08 Million - $8 Million	582,464 Added 94.76%	1,197,164 $12.3 Million
Q3 2018 Nov 13, 2018	BUY	$12.7 - $15.79 $416,356 - $517,659	32,784 Added 5.63%	614,700 $0
Q2 2018 Aug 10, 2018	BUY	$10.99 - $44.21 $5.66 Million - $22.8 Million	515,048 Added 770.25%	581,916 $0
Q4 2017 Feb 09, 2018	BUY	$35.44 - $63.76 $2.37 Million - $4.26 Million	66,868	66,868 $2.51 Million

Others Institutions Holding PRTA

# of Institutions

198

Shares Held

44.5M

Call Options Held

601K

Put Options Held

259K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $730M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account